Idexx Laboratories Flashes Improved RS Rating

On Wednesday, Idexx Laboratories (IDXX) received a positive adjustment to its Relative Strength (RS) Rating, from 70 to 75. Idexx Laboratories is trying to complete a cup without handle with a 574.09 buy point. See if the stock can clear the breakout price in volume at least 40% above average.

When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

IBD’s proprietary rating identifies price action with a 1 (worst) to 99 (best) score. The grade shows how a stock’s price behavior over the last 52 weeks stacks up against all the other stocks in our database.

Over 100 years of market history shows that the stocks that go on to make the biggest gains typically have an RS Rating of over 80 in the early stages of their moves. See if Idexx Laboratories can continue to rebound and clear that threshold.

See How IBD Helps You Make More Money In Stocks


Idexx Laboratories showed 43% EPS growth in the latest quarterly report. Sales gains came in at 19%. The company is expected to report its latest performance numbers on or around April 30.

Idexx Laboratories holds the No. 3 rank among its peers in the Medical-Systems/Equipment industry group. Inmode (INMD) is also among the group’s highest-rated stocks.


Stocks With Rising Relative Strength Ratings

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Find Top Stocks Near A Buy Point With IBD Leaderboard

Most Related Links :
newsbinding Governmental News Finance News

Source link

Back to top button